0	10	Inhibition	Inhibition	NNP
11	13	of	of	IN
14	22	NF-kappa	NF-kappa	NNP
23	24	B	B	NNP
25	27	by	by	IN
28	34	sodium	sodium	NN
35	45	salicylate	salicylate	NN
46	49	and	and	CC
50	57	aspirin	aspirin	NN
58	59	[	[	(
59	62	see	see	VB
63	71	comments	comment	NNS
71	72	]	]	)
74	77	The	the	DT
78	91	transcription	transcription	NN
92	98	factor	factor	NN
99	106	nuclear	nuclear	JJ
107	119	factor-kappa	factor-kappa	NN
120	121	B	B	NNP
122	123	(	(	(
123	131	NF-kappa	NF-kappa	NNP
132	133	B	B	NNP
133	134	)	)	)
135	137	is	be	VBZ
138	146	critical	critical	JJ
147	150	for	for	IN
151	154	the	the	DT
155	164	inducible	inducible	JJ
165	175	expression	expression	NN
176	178	of	of	IN
179	187	multiple	multiple	JJ
188	196	cellular	cellular	JJ
197	200	and	and	CC
201	206	viral	viral	JJ
207	212	genes	gene	NNS
213	221	involved	involve	VBN
222	224	in	in	IN
225	237	inflammation	inflammation	NN
238	241	and	and	CC
242	251	infection	infection	NN
252	261	including	include	VBG
262	275	interleukin-1	interleukin-1	NN
276	277	(	(	(
277	281	IL-1	IL-1	NNP
281	282	)	)	)
282	283	,	,	,
284	288	IL-6	IL-6	NNP
288	289	,	,	,
290	293	and	and	CC
294	302	adhesion	adhesion	NN
303	312	molecules	molecule	NNS
312	313	.	.	.

314	317	The	the	DT
318	335	anti-inflammatory	anti-inflammatory	JJ
336	341	drugs	drug	NNS
342	348	sodium	sodium	NN
349	359	salicylate	salicylate	NN
360	363	and	and	CC
364	371	aspirin	aspirin	NN
372	381	inhibited	inhibit	VBD
382	385	the	the	DT
386	396	activation	activation	NN
397	399	of	of	IN
400	408	NF-kappa	NF-kappa	NNP
409	410	B	B	NNP
410	411	,	,	,
412	417	which	which	WDT
418	425	further	further	RB
426	434	explains	explain	VBZ
435	438	the	the	DT
439	448	mechanism	mechanism	NN
449	451	of	of	IN
452	458	action	action	NN
459	461	of	of	IN
462	467	these	these	DT
468	473	drugs	drug	NNS
473	474	.	.	.

475	479	This	this	DT
480	490	inhibition	inhibition	NN
491	500	prevented	prevent	VBD
501	504	the	the	DT
505	516	degradation	degradation	NN
517	519	of	of	IN
520	523	the	the	DT
524	532	NF-kappa	NF-kappa	NNP
533	534	B	B	NNP
535	544	inhibitor	inhibitor	NN
544	545	,	,	,
546	547	I	i	NN
548	553	kappa	kappa	NN
554	555	B	B	NNP
555	556	,	,	,
557	560	and	and	CC
561	570	therefore	therefore	RB
571	579	NF-kappa	NF-kappa	NNP
580	581	B	B	NNP
582	585	was	be	VBD
586	594	retained	retain	VBN
595	597	in	in	IN
598	601	the	the	DT
602	609	cytosol	cytosol	NN
609	610	.	.	.

611	617	Sodium	sodium	NN
618	628	salicylate	salicylate	NN
629	632	and	and	CC
633	640	aspirin	aspirin	NN
641	645	also	also	RB
646	655	inhibited	inhibit	VBD
656	664	NF-kappa	NF-kappa	NNP
665	676	B-dependent	b-dependent	JJ
677	690	transcription	transcription	NN
691	695	from	from	IN
696	699	the	the	DT
700	702	Ig	Ig	NNP
703	708	kappa	kappa	NN
709	717	enhancer	enhancer	NN
718	721	and	and	CC
722	725	the	the	DT
726	731	human	human	JJ
732	748	immunodeficiency	immunodeficiency	NN
749	754	virus	virus	NN
755	756	(	(	(
756	759	HIV	HIV	NNP
759	760	)	)	)
761	765	long	long	JJ
766	774	terminal	terminal	JJ
775	781	repeat	repeat	NN
782	783	(	(	(
783	786	LTR	LTR	NNP
786	787	)	)	)
788	790	in	in	IN
791	802	transfected	transfecte	VBN
803	804	T	t	NN
805	810	cells	cell	NNS
810	811	.	.	.